Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

SAN MARINO, Calif., March 25 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent, Rexin-G.